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Abstract
Background: Skin cancer is a growing public health problem in South Africa due to its high ambient ultraviolet
radiation environment. The purpose of this study was to estimate the annual health system costs of cutaneous
melanoma, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) in South Africa, incorporating both the
public and private sectors.
Methods: A cost-of-illness study was used to measure the economic burden of skin cancer and a ‘bottom-up’
micro-costing approach. Clinicians provided data on the patterns of care and treatments while national costing
reports and clinician fees provided cost estimates. The mean costs per melanoma and per SCC/BCC were extrapolated
to estimate national costs using published incidence data and official population statistics. One-way and probabilistic
sensitivity analyses were undertaken to address the uncertainty of the parameters used in the model.
Results: The estimated total annual cost of treating skin cancers in South Africa were ZAR 92.4 million (2015)
(or US$15.7 million). Sensitivity analyses showed that the total costs could vary between ZAR 89.7 to 94.6 million
(US$15.2 to $16.1 million) when melanoma-related variables were changed and between ZAR 78.4 to 113.5 million
($13.3 to $19.3 million) when non-melanoma-related variables were changed. The primary drivers of overall costs were
the cost of excisions, follow-up care, radical lymph node dissection, cryotherapy and radiation therapy.
Conclusion: The cost of managing skin cancer in South Africa is sizable. Since skin cancer is largely preventable
through improvements to sun-protection awareness and skin cancer prevention programs, this study highlights
these healthcare resources could be used for other pressing public health problems in South Africa.
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Background
In South Africa, among the white population, there is
one of the highest incidences of malignant melanoma in
the world and concern for skin cancer overall has grown
in recent years. The estimated yearly incidence of malig-
nant melanoma is 4.76 per 100,000 persons overall and
19.2 per 100,000 in whites [1]. In 2009, the Western
Cape of South Africa’s incidence for whites was unoffi-
cially reported as high as 69 per 100,000 population [2].
South Africans are especially susceptible to skin cancer
due to their exposure to year-round high ambient solar
ultraviolet radiation (UV) and latitude (22–34°S) [3]. In a
population of 54 million, the racial mix within South
Africa shows a diverse population, consisting of black
(80.2 %), white (8.4 %), coloured (8.8 %) and Asian/Indian
(2.5 %) populations [4]. “Coloured” is a Statistics South
Africa non-derogatory term referring to people of mixed
race in South Africa. The skin pigmentation of South
African populations varies widely and although whites are
most susceptible to skin cancer, skin cancer occurs in all
persons regardless of their skin pigment. Squamous cell
carcinoma (SCC), basal cell carcinoma (BCC) and cutane-
ous melanoma (CM) have the highest incidence in white
people, followed by coloureds and has considerably lower
incidence in both blacks and Asian/Indians [1]. However,
black South Africans often present to doctors late when
their melanoma has already metastasized. Research has
also found that there is a high risk of developing SCC in
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human immunodeficiency virus (HIV)-positive South
Africans [5].
The South African healthcare system has made progress
towards meeting the Millennium Development Goals, al-
though in order to reach these goals and continue an up-
wards trajectory, significant improvements still remain
necessary [6]. The increasing incidence of skin cancers will
demand larger amounts of scarce healthcare resources
and will compound the stress already placed on a strained
public healthcare system. The expected rising incidence of
skin cancer has already been seen for CM in the Cape [7]
and possibly for all cancers, including CM, in the country
as a whole [8]. Targeting diseases like skin cancer which
are largely preventable through better awareness and pro-
motion of healthy behaviours among its citizens is crucial
to minimizing this healthcare resource burden.
The purpose of this study was to estimate the yearly
health system costs of CM, SCC and BCC in South Africa,
incorporating both the public and private sectors. In doing
so, it will provide a better understanding of this disease
burden, the health resources used in its current manage-




A cost-of-illness study was used to measure the economic
burden of skin cancer including malignant CM, SCC and
BCC. A ‘bottom-up’ micro-costing approach was taken in
order to estimate the economic burden of skin cancer
diagnosis and treatment [10, 11]. The bottom-up approach
identifies the patterns of care for skin cancer, assigns unit
costs to each specific intervention in the care pathway and
aggregates the total costs of care incurred by patients [11].
This enables extrapolation of costs on a national level
based on the numbers of patients receiving each type of
treatment using incidence data. We abided by all ethics
principles and since we used publicly available, population
level data, with no individual details, ethical clearance was
not needed.
Model
A model was constructed to describe the key pathways of
care in skin cancer management in South Africa using the
computer program TreeAge Pro Version 2015 (TreeAge
Software Inc, Massachusetts,USA). This tool is useful be-
cause it can accommodate the continuum of care from
diagnosis through to treatment and follow-up. The model
combines probabilities of each care pathway and their
costs. In the absence of South African published skin
cancer clinical guidelines, the pathways were created by
a team of currently practising and experienced South
African dermatologists. Consequently, these pathways
reflect the current ‘real life’ patterns for private and
public skin cancer care. The patterns of care aligned
well with several international clinical practice guide-
lines for management of malignant skin cancers including
those from the United States (US) National Comprehen-
sive Cancer Network, Cancer Care Ontario, European So-
ciety for Medical Oncology and the Australian Cancer
Network [12]. Separate pathways were developed for CM
versus SCC and BCC (Fig. 1). The time horizon was
12 months because for most cases, treatments were com-
pleted within this period.
Model inputs
Assumptions were necessary to complete the cost and
probability values for the pathways and these are clearly
stated underneath and in Tables 1 and 2.
Probabilities
A thorough literature search was performed to identify
published studies in the medical literature and organisa-
tional websites that report on the patterns of skin cancer
care in South Africa. There were no data on the probabil-
ities of different treatment options typically used in South
Africa, and we relied on two clinical experts for these esti-
mates. The estimates were varied around plausible ranges
and tested in sensitivity analyses. Table 1 provides the
values used in the model, their ranges tested and sources.
For simplicity, and due to data restrictions, a number of
assumptions were necessary. These included: a person
would only develop one skin cancer in the 12-month
period; a person who received sentinel lymph node dissec-
tion would have an overnight stay in hospital prior to the
procedure; all suspected melanomas had a diagnostic bi-
opsy; treatments were all one-offs; benign lesions received
no treatment; and no re-treatments occurred.
Costs
Healthcare resource usage was identified through the
treatment descriptions. The main components of costs
in the model were: initial and follow-up consultations by
general practitioners or specialists, pathology and treat-
ment alternatives for example, surgical excisions, topical
creams, photodynamic therapy etc. In the public health
system, most patients will be seen by a general practi-
tioner at the primary health care level and subsequently
treated in a secondary level public hospital. Costs for
public hospital services were derived from the National
Public Hospital Tariff schedule [13]. Costs for medicines
such as imiquimod 5 % cream and interferon 2b were
sourced from the South African Master Procurement
List [14]. Costs for patients in the private system were
derived from fees charged by private practitioners with
recent invoices reviewed as evidence of these. Although
charges for services are not strictly economic costs, they
do represent a monetary value of the present care
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provided to patients for skin cancer. Costs which were
not in the above resources were converted into Rand
from costs in the Australian healthcare system (Table 2).
We combined the private and public costs into weighted
averages for each item (Table 2) in recognition of the 84 %
public and 16 % private system split in South Africa [8].
Analyses
All costs are presented in 2014/15 South African Rand
(ZAR) and US dollars ($). The currency exchange rate was
1 ZAR = 0.1697 US using the Cochrane cost converter at
http://eppi.ioe.ac.uk/costconversion/default.aspx which in-
flates and converts currencies simultaneously using
purchasing power parities. The model aggregated all
probabilities and costs to derive the mean cost per per-
son for malignant CM or SCC/BCC. One-way sensitivity
analysis was performed on all estimates to determine the
reasonable variation in values where uncertainty and vari-
ation in clinical practice exists. Probability distributions
were assigned to parameters with the highest amount of
uncertainty and a probabilistic sensitivity analysis was per-
formed to calculate the mean cost of CM and SCC/BCC
skin cancer.
The mean costs per melanoma and per SCC/BCC were
extrapolated to estimate national costs using published in-
cidence data from 2000 to 2004 [1] and official population
statistics [4]. Notifications of all histologically-confirmed
cases of SCC, BCC and malignant CM are received by the
South African National Cancer Registry (NCR). The NCR
is the largest and most representative cancer registry in
South Africa. Reporting processes are robust with quality-
assurance measures in place [8]. However, between 2005
and 2011, this voluntary registry did not receive all private
hospital registrations (up to 16 % of all patients). The im-
pact of this was the underestimation of the true number
of cases. A study by Singh et al. [8] has quantified this gap
in case numbers for cancers overall (4 %) and our esti-
mates were adjusted accordingly. The Singh [8] study did
not include non-melanoma skin cancers, however it is as-
sumed the reporting issue for these cancers would be
equivalent. The ethnic group incidences sourced from
Norval et al. [1] were not complete. The ethnic group of
patients were unspecified in 93 % of cases. The study used
a hot-deck imputation method to allocate surnames into
ethnic groups, although a large proportion of surnames
could not be allocated. A sub-group ‘unknown race’ was
created to represent this population.
Benign skin lesions, suspected to be malignant, are often
included in estimates of skin cancer cost [10, 15]. We also
modelled the diagnostic or ‘screening’ costs of skin cancers
where the medical consultation involved investigation of a
suspicious skin lesion that was subsequently found to be
benign and required no further treatment. The proportion
of skin cancer investigations which were benign was
Fig. 1 Structure of the model
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sourced through the expert opinion of practising medical
staff, although it is acknowledged the accuracy of the
number of SCCs and BCCs treated by GPs is unknown.
Results
Our model predicted that the annual total cost of
treating skin cancers in South Africa were ZAR 92.4
million ($15.7 million). This assumes all those
diagnosed are treated as per local clinical practice
however, despite some anecdotal evidence that loss to
follow up may be high in the public sector in South
Africa. The estimated costs were ZAR 81.6 million
($13.8 million) for non-melanoma skin cancer and
ZAR 10.8 million ($1.8 million) for CM (Table 3).
When lesions suspected to be skin cancers, but were di-
agnosed as benign, were considered, these additional
Table 1 Estimated probabilities, sensitivity values and sources
Probabilities Used in model Sensitivity valuesa Sources/assumptions
Melanoma
Proportion of cases of suspected melanoma are seen
in public or private setting
20 %/80 % 15 %/85 %,
25 %/75 %
Expert opinion, persons with white skin are
more susceptible to skin cancers and seen
in private settings
Proportion of cases seen by GP who suspects a melanoma
refers to a dermatologist or surgeon
80 % 70 %, 90 % Assumption based on convenience and high
likelihood in public hospital to refer to specialist
Proportion of suspected melanoma that were malignantb 80 % 75 %, 85 % Expert opinionc, Fong 2014 [12]
Melanoma is surgically excised 100 % 87.9 % Expert opinion (all melanomas including
advanced) Vallejo-Torres 2014 [10]
Melanoma is greater than 1 mm thick 30 % 20 %, 40 % Expert opinionc
Melanoma greater than 1 mm thick has metastasized 20 % 15 %, 25 % Expert opinionc
Melanoma with no metastases is treated with interferon
2b alpha
3 % 2 %, 4 % Expert opinionc, Fong 2014 [12]
Melanoma greater than 1 mm thick has metastases in
lymph nodes
30 % 25 %, 35 % Expert opinionc, published literature - ranges
from 4 to 44 %
Melanoma with lymph node metastases is treated with
radical LND
100 % – Expert opinionc: All those with SLNB get RLND.
Melanoma is treated by radiotherapy 5 % 4 %, 6 % Expert opinionc, most with metastases will
only get palliative care, Fong 2014 [12]
Melanoma is treated with chemotherapy 10 % 5 %, 7 % Expert opinionc, Fong 2014 [12]
Non-melanoma (NM)SCC or BCC
NM is treated by a GP in the public setting 100 % – Expert opinionc, all seen first by a GP, (same
for Aust. and England)
NM case is referred to a dermatologist 60 % 50 %, 70 % Expert opinionc 60 % for dermatologist or
surgeon
Suspected NM is confirmed to be malignantc 85 % 80, 90 % Expert opinionc
SCC is >2 cm diameter 10 % 8 %, 12 % Expert opinionc
Large SCC is positive and surgeon treats by radical LND 20 % 15 %, 20 % Expert opinionc, Fong 2014 [12]
NM is treated by:
Surgical excision 80 % 86.0 % Expert opinionc, Vallejo-Torres 2014 [10],
Fong 2014 [12]
Cryotherapy 10 % 3.1 % As above
Curette and diathermy/electrodesiccation 5 % 7.5 % As above
Topical cream 3 % 0.5 % As above
Photodynamic therapy 1 % 0.8 % As above
Radiotherapy 1 % 1.7 % As above
LND lymph node dissection, GP general practitioner, SCC squamous cell carcinoma, BCC basal cell carcinoma
aThe sensitivity values are the high and low estimates used in the sensitivity analysis. These are based on sources in the literature or judged as plausible ranges
around the best estimate used in the model base case. For probabilistic sensitivity analyses, beta distributions were assigned to probabilities to account
for uncertainty
bExpert opinion is from practicing dermatologists and practicing doctors
cLesions suspected of being Malignant are often investigated and later diagnosed as benign
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costs were ZAR 45.1 million ($7.7 million). The total skin
cancer costs per ethnic group were highest for whites
(ZAR 30.5 million ($5.2 million) or 33.0 %), coloureds
(ZAR 9.69 million ($1.6 million) or 10.5 %), black Africans
(ZAR 7.84 million ($1.3 million) or 8.5 %) and lowest for
Asians/Indians (ZAR 0.44 million ($0.1 million) or 0.5 %)
(Table 3). The remaining ZAR 44.0 million ($7.5 mil-
lion) (47.6 %) was attributed to persons of ‘unknown
race’. The validity of the cost distribution across the
ethnic subgroups is diminished due to the ‘unknown
race’ subgroup representing almost half the total
costs. Consequently, the estimates are grossly
underestimated and are a limitation of the current
data quality in South Africa.
Sensitivity analyses showed that the annual cost of skin
cancers could vary between ZAR 89.7 to ZAR 94.6 mil-
lion ($15.2 to $16.1 million) when melanoma-related
variables were changed and between ZAR 78.4 to ZAR
113.5 million ($13.3 to $19.3 million) when non-
melanoma-related variables were changed. The primary
driver in costs were the costs of follow-up and investiga-
tions, cost of excision and histopathology and the pro-
portion of public patients, melanoma >1 mm and non-
melanoma referrals.










Cost of a dermatologist or surgeon visit 458 268 298 51 UPFS tariffs #1012 + #1010 (facility fee level 2)
Cost of a GP visit 335 158 186 32 UPFS tariff #1011 + #1010 (facility fee level 2), private:
review of invoices
Cost of a diagnostic biopsy (includes
immunohistology)
750 593 618 105 UPFS tariff #1112 + #1110 (facility fee level 2),
private: R750 dxbiopsy + excision
Cost of excision 4643 593 1241b 211 UPFS tariff #1112 + #1110 (facility fee level 2), private:
review of invoices
Cost of an excision with reconstructive surgery 4433 2091 2466 418 UPFS tariff #1612 cosmetic surgery cat A -specialist
\practitioner + 75 facility feeb
Cost of cryotherapy 1257 593 699 119 UPFS tariff #1112 + #1110 (facility fee level 2),b
Cost of topical cream 548 548 548 93 Master procurement list - Imiquimod 5 % 12 sachets
#180346230
Cost of photodynamic therapy 2514 1186 1399 237 UPFS tariff #1112 + #1110 (facility fee level 2), need 2
sessionsb
Cost of curettage and cautery 1257 593 699 119 UPFS tariff #1112 + #1110 (facility fee level 2),b
Cost of radiotherapy - whole course 62334 29403 34672 5884 Annex N for Radiology - MR planning for radiotherapy
course (oncol radiotherapy not available) Have used
Aust. Price $7325 for whole coursec
Cost of chemotherapy - whole course 31185 31185 31185 5292 Dacarbazine was not on the procurement list therefore
price is based on fotemustine, AU $7769 per coursec
Cost of treatment for SCC or BCC in primary
care by GP
1018 480 566 96 UPFS tariff #1112 + #1010 (facility fee level 2),b
Cost of adjuvant immunotherapy with interferon -
interferon alpha, 1 syringe injection
367 367 367 62 Master procurement list interferon alpha 2b syringe
9 MIU/0.5 mL #180348820 - daily injection for
10–24 weeks, then 3 ×/week for up to 6 mths
Cost of PET scan 11195 4224 5339 906 UPFS tariff #1952 + #1950 (facility fee level 2), private:
review of invoices
Cost of a radical lymph node dissection 6632 593 1559 265 UPFS tariff #1112 + #1010 (facility fee level 2),
Cost of sentinel lymph node biopsy 750 593 618 105 UPFS tariff #1112 + #1010 (facility fee level 2),b
Cost of follow up 1694 158 404 69 UPFS tariff #1031 + #1010 (facility fee level 2)
Cost of hospitalisation - 1 night for melanoma
with SLNB
2105 993 1171 199 UPFS tariff #0612 + #0610 (facility fee level 2) same as
day patient #0663b
UPFS Uniform Patient Fee Schedule, GP general practitioner, SLNB sentinel lymph node biopsy, PETpositron emission tomography, SCC squamous cell carcinoma,
BCC basal cell carcinoma, MR magnetic radiation
aWeighting based on 16 % private and 84 % public [23]. Sensitivity analyses are based on the private and public sector values
bIn the absence of a private fee, it was assumed a 2.12 to 1.00 ratio of private to public based on the cost of a GP visit differential between private and
public sectors
cConverted to ZAR by http://eppi.ioe.ac.uk/costconversion/default.aspx
Note: Sensitivity values were created with a 15 % change in the public sector probability when weighting the cost. (low = 84 %*0.85;high = 84 %*1.15). For
probabilistic sensitivity analyses, gamma distributions were assigned to costs to account for uncertainty
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Discussion
This is the first cost-of-illness study performed on skin
cancer in South Africa. The total cost of treating skin can-
cer was estimated to be in the vicinity of ZAR 92.4 million
($15.7 million) a year in South Africa. This is likely to be
underestimated due to not all BCC being monitored
throughout South Africa and also excludes the costs asso-
ciated with potential life lost and lost productivity, as in-
cluded in other studies [16]. However, putting this finding
into perspective, if skin cancer was prevented and the
funds currently spent on diagnosis and treatment were re-
deployed, ZAR 92.4 million ($15.7 million) could provide
two doses of human papilloma virus (HPV) vaccine to
305,000 girls in public schools (this translates to 67 %
coverage of Grade 4 girls aged 9 and older, based on 2014
data)1. Cost-of-illness studies are limited for health policy
decisions because they do not provide information on
cost-effectiveness and therefore, cannot guide decisions
about the wisest choice of interventions to be provided.
However, skin cancer is preventable if sun exposure is not
excessive and therefore cost studies are important and
useful for raising awareness for preventable diseases, and
they illustrate the costs that may be averted through pre-
vention programs. Many studies have previously shown
that prevention initiatives such as sunscreen promotion,
educational programs, and multifaceted programs are
cost-effective [17–22]. These programs have been effective
in the context of organisational settings such as educa-
tional locations as well as workplaces and sporting bodies
and at systemic levels through mass media campaigns.
Skin cancer is known to be caused by solar ultraviolet ra-
diation and sun protection strategies are well-established
in primary prevention. Preventing skin cancer through
clothing, hats, sunscreen and seeking shade when out-
doors, are known to reduce skin cancer development. In a
strained healthcare system, understanding the impact of
averting skin cancers emphasizes the economic import-
ance of skin cancer prevention as a way of not only pro-
moting health but freeing health resources for other
conditions. Due to the lack of recent cancer statistics
and monitoring systems, the study highlights the need
for efficient surveillance and data capturing, increased
research, improved awareness and informed prevention
of skin cancer.
South Africa has a pluralistic health system, where the
public and private sectors have radically different resources .
Approximately 80 % of the population is served by an
under-resourced and severely strained public health sys-
tem where treatment is provided free of charge [23]. The
remaining 20 % of the population (mostly those who are
formally employed) receives world-class health care from
private healthcare providers, through private medical in-
surance. Health resources are heavily skewed towards the
private sector, which serves the minority of the country’s
population. There are racial differences in health care util-
isation: 60 % of white and coloured adults visit a health
professional in a year, of which 81 % were to a private fa-
cility, compared to 44 % of black African adults, of which
34 % were to private facilities [24]. The lower rates of
black South Africans seeking medical care are explained,
Table 3 Estimates of national costs of skin cancer (2014/15 ZAR, $US)
Melanoma BCC and SCC Total
Mean costs per suspected case ZAR 3566 $605 ZAR 2154 $366 -
Mean costs per diagnosed case ZAR 4197 $712 ZAR 2767 $470 -
<1 mm ZAR 2931 $497
>1 mm ZAR 7149 $1213
Incidence per 100,000a 4.77 54.6 59.4
million million million
Total costs ZAR 10.80 $1.8 ZAR 81.60 $13.8 ZAR 92.40 $15.7
By racial group
Blacks ZAR 2.09 $0.4 ZAR 5.76 $1.0 ZAR 7.84 $1.3
Asians/indians ZAR 0.05 $0.0 ZAR 0.38 $0.1 ZAR 0.44 $0.1
Coloureds ZAR 1.04 $0.2 ZAR 8.66 $1.5 ZAR 9.69 $1.6
Whites ZAR 3.67 $0.6 ZAR 26.82 $4.6 ZAR 30.49 $5.2
Unknown race ZAR 3.96 $0.7 ZAR 40.06 $6.8 ZAR 44.02 $7.5
By Gender
Men ZAR 6.10 $1.0 ZAR 54.71 $9.3 ZAR 60.81 $10.3
Women ZAR 4.70 $0.8 ZAR 26.96 $4.6 ZAR 31.67 $5.4
SCC squamous cell carcinoma, BCC basal cell carcinoma, ZAR South African Rand
aNorval 2014 [1] - Adjusted by 1.04 for under-reporting as per Singh 2015 [8]
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in part, by high travel costs to attend health care, out-of-
pocket cost burden, long queues, perceived disrespectful
treatment by facility staff, medicine stock-outs, perceived
ineffective care and a preference to see traditional healers
[25]. This behaviour has affected the presentation of mel-
anoma in black South Africans with nodal disease occur-
ring in more than one third of patients at their initial visit
and 15 % already having disseminated metastatic disease
[26, 27]. The lack of concern for skin problems relative to
other serious health worries for people with HIV/AIDS
may also be an additional reason for late presentation. Be-
cause black South Africans are not immune to skin can-
cers and because of high HIV prevalence, sun protection
messages remain important [28].
A recent systematic review of studies reporting national
costs of skin cancers and cost-effectiveness studies of pre-
vention programs indicates the significant economic bur-
den of skin cancer around the world [29]. The review
found that in 16 studies, as a ratio to the population size
of the country, the highest annual direct health system
costs, is felt in Australia, New Zealand, Sweden and
Denmark. If the results of the present analysis were avail-
able at the time of the review, it would have showed that
South Africa was lowest for melanoma burden but higher
than Brazil for non-melanoma cost burden (as a ratio of
2013 euros to population size) [29].
This analysis is limited because it relies on simplifying
assumptions and on limited expert opinion for the treat-
ment probabilities in the model rather than on large ob-
servational studies. Although not ideal, such data is not
available in South Africa. Nevertheless, our estimates are
‘real life’, contemporary and the types and frequencies of
treatments are comparable to those of the general inter-
national literature and guidelines for skin cancer [12]. For
example, excision is clearly the preferred and dominant
approach for non-melanoma skin cancer and melanoma.
In these types of modelling studies, gaps commonly occur
and reliance on expert opinion for these estimates is often
Fig. 2 Results of sensitivity analysis for melanoma costs (ZAR)
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necessary [30]. Treatments of skin cancers are also
changing. New targeted therapies for advanced melan-
oma (e.g., dabrafenib, ipilimumab) are now available in
other countries and are very expensive. If these are ac-
cepted for use in South Africa, the estimated cost of
ZAR 10.8 million (US$1.6 million) for treating CM will
be even higher. Lastly, the incidence data used to extrapo-
late the total costs were calculated using data from 2000 to
2004, and may no longer be accurate, and under-reporting
is strongly suspected for BCCs because health care services
do not fully cover all areas of South Africa [1].
It is standard practice in health economics to acknow-
ledge and transparently quantify the uncertainty present
in modelling studies [30]. We undertook one-way sensitiv-
ity analyses to assess parameter uncertainty and the tor-
nado figures (Figs. 2 and 3) outline the variables which
impact the costing results the most. An additional use of
the sensitivity analysis in this study is that it highlights
which variables new research could concentrate on to ob-
tain better estimates. Those with high uncertainty and sig-
nificant influence on the results are displayed at the top of
the tornado diagrams (Figs. 2 and 3). They include the
costs of follow-up and investigations, cost of excision
and histopathology, the proportion of public patients,
melanoma size and non-melanoma referrals. Beyond
skin cancer, dedicated investment for capturing medical
surveillance data in order to create accurate costing
models in the South African setting is necessary. This
would assist decision-makers in allocating resources where
the most public health gain and least costly choices are
possible. An efficient health system is one where spending
occurs wisely, wastage is eliminated and where the most
South Africans can gain better health outcomes.
Conclusion
In conclusion, this study is a first attempt to provide a
snapshot on the financial burden of skin cancer in South
Africa. Subject to the caveats herein, the cost of skin
cancer in South Africa is substantial and improvements
to sun-protection awareness and behaviours are likely to
avoid skin cancer development. In doing so, the health
of individuals will be improved while also releasing
scarce healthcare resources for other pressing public
health problems.
Endnotes
1HPV vaccine was approved in the public sector in
South Africa in 2014 (school-based program for girls in
Grade 4 in government schools). Vaccines are to be
provided to approximately 450,000 girls who will re-
ceive a 2 dose vaccine, at a cost of R157 per dose (GSK
tender prices reported by MSF). In round 1 of vaccin-
ation reached 412,617 girls and round 2 reached 422,000
girls. Authors own calculations based on data included in:
Richter, K (2014) Implementation of HPV vaccination in
South Africa, https://www.phasa.org.za/implementation-
Fig. 3 Results of sensitivity analysis for non-melanoma costs (ZAR)
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hpv-vaccination-south-africa/ Sans Frontieres (2015). The
Right Shot: Bringing Down Barriers to Affordable and




AIDS: Acquired Immunodeficiency Disease; BCC: basal cell carcinoma;
CM: cutaneous melanoma; HIV: human immunodeficiency virus; HPV: Human
papilloma virus; NCR: National Cancer Registry; SCC: Squamous cell carcinoma;
USD: United States Dollars; ZAR: South African Rand.
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